Shirong Li1 , Huahong Wang2 , Jichun Hu3, Nan Li4 , Yulan Liu5, Zitao Wu1, Yue Zheng2, Honghua Wang3, Kai Wu4, Hui Ye5, and Jianyu Rao6
Department ofGastroenterology, Beijing Army General Hospital, Beijing, China Department of Gastroenterology, First Hospital of Beijing University, Beijing, China 3 Department of Gastroenterology, Beijing Haidian Hospital,Beijing, China 4 Department of Gastroenterology, 309 Hospital of People's Liberation Army, Beijing, China 5 Department of Second Hospital of Beijing University, Beijing, China 6 Department of Pathology andLaboratory Medicine, David Geffen School of Medicine, and Department of Epidemiology, School of Public Health, University of California at Los Angeles, Los Angeles, CA, United States of AmericaCorrespondence to: 1. Jianyu, Rao, M.D. Associate Professor Department of Pathology and Laboratory Medicine David Geffen School of Medicine Jonsson Comprehensive Cancer Center University of California atLos Angeles Los Angeles, CA 90095 USA Tel.310-794-1567 Fax.310-825-7795 Email: firstname.lastname@example.org
2. Shirong Li, M.D Professor Department of Gastroenterology and Center of Colon disease BeijingArmy General Hospital Beijing, 100700 China E-mail: email@example.com firstname.lastname@example.org
ABSTRACT BACKGROUND: Guaiac-based chemical Fecal Occult Blood Tests (CFOBT) have been widelyused for colorectal cancer screening in Western countries. It is recommended that the test be performed on three-consecutive stool samples. The goal of this study was to determine thecost-effectiveness of a new immunochemical FOBT method (Hemosure IFOBT) for colon cancer screening in the Chinese population, and whether the new assay could reduce the number of samples needed for the test. In...